JP2009235086A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009235086A5 JP2009235086A5 JP2009139245A JP2009139245A JP2009235086A5 JP 2009235086 A5 JP2009235086 A5 JP 2009235086A5 JP 2009139245 A JP2009139245 A JP 2009139245A JP 2009139245 A JP2009139245 A JP 2009139245A JP 2009235086 A5 JP2009235086 A5 JP 2009235086A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- valsartan
- pharmaceutically acceptable
- acceptable salt
- calcium salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 18
- 229960004699 valsartan Drugs 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 17
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 14
- 230000008018 melting Effects 0.000 claims 10
- 238000002844 melting Methods 0.000 claims 10
- 238000004279 X-ray Guinier Methods 0.000 claims 6
- 239000000843 powder Substances 0.000 claims 6
- 159000000007 calcium salts Chemical class 0.000 claims 5
- 230000009477 glass transition Effects 0.000 claims 5
- 150000004682 monohydrates Chemical class 0.000 claims 4
- -1 valsartan magnesium salt Chemical class 0.000 claims 4
- ODYFGDACHPDINU-UHFFFAOYSA-N O.O.O.[Ca] Chemical compound O.O.O.[Ca] ODYFGDACHPDINU-UHFFFAOYSA-N 0.000 claims 3
- 159000000003 magnesium salts Chemical class 0.000 claims 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 2
- 102000003729 Neprilysin Human genes 0.000 claims 2
- 108090000028 Neprilysin Proteins 0.000 claims 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 2
- 150000004686 pentahydrates Chemical class 0.000 claims 2
- 150000004684 trihydrates Chemical class 0.000 claims 2
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 229940123934 Reductase inhibitor Drugs 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000002170 aldosterone antagonist Substances 0.000 claims 1
- 229940083712 aldosterone antagonist Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- MMFBVFWEERQGJK-UHFFFAOYSA-N calcium;tetrahydrate Chemical compound O.O.O.O.[Ca] MMFBVFWEERQGJK-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 150000004687 hexahydrates Chemical class 0.000 claims 1
- 238000002329 infrared spectrum Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- YYINWHOQKIUBNL-UHFFFAOYSA-N magnesium;trihydrate Chemical compound O.O.O.[Mg] YYINWHOQKIUBNL-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 150000004685 tetrahydrates Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35419902P | 2002-02-04 | 2002-02-04 | |
| US60/354,199 | 2002-02-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565980A Division JP4895475B2 (ja) | 2002-02-04 | 2003-02-03 | バルサルタンの塩類 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009235086A JP2009235086A (ja) | 2009-10-15 |
| JP2009235086A5 true JP2009235086A5 (enExample) | 2010-07-29 |
| JP5303370B2 JP5303370B2 (ja) | 2013-10-02 |
Family
ID=27734333
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565980A Expired - Fee Related JP4895475B2 (ja) | 2002-02-04 | 2003-02-03 | バルサルタンの塩類 |
| JP2009139245A Expired - Fee Related JP5303370B2 (ja) | 2002-02-04 | 2009-06-10 | バルサルタンの塩類 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565980A Expired - Fee Related JP4895475B2 (ja) | 2002-02-04 | 2003-02-03 | バルサルタンの塩類 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US6869970B2 (enExample) |
| EP (1) | EP1474402A1 (enExample) |
| JP (2) | JP4895475B2 (enExample) |
| KR (3) | KR20040081178A (enExample) |
| CN (2) | CN101633646B (enExample) |
| AU (1) | AU2003214054B2 (enExample) |
| BR (1) | BR0307442A (enExample) |
| CA (2) | CA2776902A1 (enExample) |
| CO (1) | CO5611107A2 (enExample) |
| EC (1) | ECSP045221A (enExample) |
| MX (1) | MXPA04007525A (enExample) |
| NO (1) | NO328155B1 (enExample) |
| NZ (1) | NZ534560A (enExample) |
| PL (1) | PL370481A1 (enExample) |
| RU (1) | RU2004126862A (enExample) |
| WO (1) | WO2003066606A1 (enExample) |
| ZA (1) | ZA200405698B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7468390B2 (en) | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
| US6869970B2 (en) * | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
| DK1515717T3 (da) * | 2002-06-13 | 2009-02-09 | Novartis Ag | Calciumsalte af indolafledte statiner |
| ES2238022T3 (es) * | 2003-03-17 | 2008-11-01 | Teva Pharmaceutical Industries Ltd. | Poliformos de valsartan. |
| JP4783733B2 (ja) * | 2003-05-16 | 2011-09-28 | ノバルティス アーゲー | バルサルタンを含む医薬組成物 |
| TW200518747A (en) * | 2003-11-14 | 2005-06-16 | Novartis Ag | Additional pharmaceutical use |
| ITMI20032267A1 (it) * | 2003-11-21 | 2005-05-22 | Dinamite Dipharma S P A In Forma A Bbreviata Diph | Procdimento per la preparzione di valsartan e suoi intermedi |
| WO2005049587A1 (en) * | 2003-11-21 | 2005-06-02 | Ranbaxy Laboratories Limited | Process for preparation of biphenyl tetrazole |
| TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
| PT1586310E (pt) * | 2004-04-15 | 2007-02-28 | Helm Ag | Processo para a preparação de adsorvatos de valsartan na forma de pó solto |
| PE20060416A1 (es) * | 2004-08-03 | 2006-06-09 | Novartis Ag | Composicion de inhibidores de renina e inhibidores de proteinas de efusion |
| WO2006021443A2 (en) * | 2004-08-26 | 2006-03-02 | Novartis Ag | Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator |
| KR20070074576A (ko) | 2004-10-29 | 2007-07-12 | 코와 가부시키가이샤 | 사구체 질환 치료제 |
| US20100028439A1 (en) * | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| US20090304797A1 (en) * | 2006-06-23 | 2009-12-10 | Tarur Venkatasubramanian Radha | Process for the Preparation of Micronized Valsartan |
| AR061627A1 (es) | 2006-06-27 | 2008-09-10 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas |
| WO2008018843A1 (en) * | 2006-08-08 | 2008-02-14 | Ulkar Kimya Sanayi Ve Ticaret As | Process for producing useful salts form of biphenyl-tetrazole compounds |
| PE20080907A1 (es) * | 2006-08-31 | 2008-08-22 | Novartis Ag | Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan |
| WO2008088727A2 (en) | 2007-01-12 | 2008-07-24 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
| US8080549B2 (en) * | 2007-01-12 | 2011-12-20 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
| CN101396366B (zh) * | 2007-09-25 | 2010-10-13 | 浙江华海药业股份有限公司 | 含缬沙坦的固体口服制剂及其制备方法 |
| ES2336755B1 (es) * | 2008-10-07 | 2011-01-21 | Activery Biotech, S.L. | Procedimiento para la preparacion de combinaciones de valsartan y simvastatina. |
| JP2011063518A (ja) * | 2009-09-15 | 2011-03-31 | Tohoku Univ | Ａｒｂ及び／又はグリタゾン系血糖降下物質を含有するｏａｔｐ−ｒ遺伝子発現増強組成物 |
| KR20130139863A (ko) | 2010-08-03 | 2013-12-23 | 노파르티스 아게 | 고도 결정질 발사르탄 |
| CN103012301B (zh) * | 2013-01-05 | 2015-06-17 | 江苏施美康药业股份有限公司 | 缬沙坦甲酯碱金属盐及其制备方法 |
| DE102014004512A1 (de) * | 2014-03-28 | 2015-10-01 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin | Anorganisch-organische Hybridverbindung |
| WO2017012600A1 (en) | 2015-07-20 | 2017-01-26 | Zentiva, K.S. | A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| EP3498698A1 (en) | 2017-12-15 | 2019-06-19 | Mankind Pharma Ltd | Solid forms of valsartan disodium and process of preparation thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122010000024I1 (de) * | 1990-02-19 | 2010-07-08 | Novartis Ag | Acylverbindungen |
| EP0820302A1 (en) * | 1995-04-07 | 1998-01-28 | Novartis AG | Combination compositions containing benazepril or benazeprilat and valsartan |
| ES2099031B1 (es) | 1995-05-31 | 1997-12-01 | Esteve Labor Dr | Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen. |
| US5877193A (en) * | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| CN1249816A (zh) * | 1997-02-28 | 2000-04-05 | 伯斯坦恩实验室股份有限公司 | 盘片中的实验室 |
| US6641886B1 (en) * | 1999-03-23 | 2003-11-04 | Flexplay Technologies, Inc. | Directory read inhibitor for optical storage media |
| JP2001155346A (ja) * | 1999-11-26 | 2001-06-08 | Toshiba Corp | 情報記録媒体、情報記録装置、情報記録方法、情報再生装置、情報再生方法 |
| SK16372002A3 (sk) | 2000-04-24 | 2003-04-01 | Teva Pharmaceutical Industries Ltd. | Zolpidem hemitartrát |
| US20020132839A1 (en) * | 2000-06-22 | 2002-09-19 | Ganter Sabina Maria | Tablet formulations comprising valsartan |
| PE20020613A1 (es) | 2000-07-19 | 2002-08-07 | Novartis Ag | Sales de (s)-n-(1-carboxi-2-metil-prop-1-il)-n-pentanoil-n-[2'-(1h-tetrazol-5-il)-bifenil-4-ilmetil]-amina como antagonista del receptor at1 |
| US6869970B2 (en) * | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
-
2003
- 2003-01-29 US US10/353,389 patent/US6869970B2/en not_active Expired - Lifetime
- 2003-02-03 RU RU2004126862/04A patent/RU2004126862A/ru unknown
- 2003-02-03 PL PL03370481A patent/PL370481A1/xx not_active Application Discontinuation
- 2003-02-03 KR KR10-2004-7012006A patent/KR20040081178A/ko not_active Ceased
- 2003-02-03 WO PCT/EP2003/001047 patent/WO2003066606A1/en not_active Ceased
- 2003-02-03 CN CN200910167071XA patent/CN101633646B/zh not_active Expired - Lifetime
- 2003-02-03 CN CNB038032600A patent/CN100548993C/zh not_active Expired - Lifetime
- 2003-02-03 AU AU2003214054A patent/AU2003214054B2/en not_active Ceased
- 2003-02-03 MX MXPA04007525A patent/MXPA04007525A/es active IP Right Grant
- 2003-02-03 KR KR1020117020401A patent/KR20110101257A/ko not_active Ceased
- 2003-02-03 EP EP03709700A patent/EP1474402A1/en not_active Withdrawn
- 2003-02-03 JP JP2003565980A patent/JP4895475B2/ja not_active Expired - Fee Related
- 2003-02-03 KR KR1020127011954A patent/KR20120054667A/ko not_active Ceased
- 2003-02-03 NZ NZ534560A patent/NZ534560A/en not_active IP Right Cessation
- 2003-02-03 CA CA2776902A patent/CA2776902A1/en not_active Abandoned
- 2003-02-03 BR BR0307442-0A patent/BR0307442A/pt active Search and Examination
- 2003-02-03 CA CA2474424A patent/CA2474424C/en not_active Expired - Fee Related
-
2004
- 2004-07-16 ZA ZA200405698A patent/ZA200405698B/en unknown
- 2004-08-04 EC EC2004005221A patent/ECSP045221A/es unknown
- 2004-09-01 NO NO20043660A patent/NO328155B1/no not_active IP Right Cessation
- 2004-09-02 CO CO04086386A patent/CO5611107A2/es not_active Application Discontinuation
- 2004-12-15 US US11/013,111 patent/US8058301B2/en active Active
-
2009
- 2009-06-10 JP JP2009139245A patent/JP5303370B2/ja not_active Expired - Fee Related
-
2011
- 2011-09-28 US US13/247,281 patent/US8329919B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009235086A5 (enExample) | ||
| RU2004126862A (ru) | Соли валсартана | |
| JP2005517696A5 (enExample) | ||
| JP2012067131A5 (enExample) | ||
| CA2682859A1 (en) | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl)indazole for treatment of abnormal cell growth in mammals | |
| JP2012508178A5 (enExample) | ||
| CA2415962A1 (en) | Valsartan salts | |
| HRP20151299T1 (hr) | Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr | |
| RU2003104789A (ru) | Соли валсартана | |
| RU2009122242A (ru) | Кристаллические формы сольватированного илапразола | |
| JP2009517023A5 (enExample) | ||
| Zhang et al. | Effect of crystal phases of titanium dioxide on adsorption performance of H2TiO3-lithium adsorbent | |
| JP2012507476A5 (enExample) | ||
| RU2008141373A (ru) | Соль алискирена и серной кислоты | |
| JP2009502780A5 (enExample) | ||
| CA2632283A1 (en) | Polymorphs of a c-met/hgfr inhibitor | |
| JP2012512885A5 (enExample) | ||
| WO2008039431B1 (en) | Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid | |
| JP2012501296A5 (enExample) | ||
| JP2007532560A5 (enExample) | ||
| JP2012531408A5 (enExample) | ||
| JP2013538849A5 (enExample) | ||
| JP2009531465A5 (enExample) | ||
| WO2009047775A3 (en) | Polymorphs of esomeprazole salts | |
| Khandavilli et al. | High solubility crystalline hydrates of Na and K furosemide salts |